Biosimilars and Biologics

Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics. This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including: Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines The safety, efficacy, and interchangeability of biologics The science and analytical chemistry associated with the manufacture of biologics Needed pharmacovigilance and adverse effect reporting systems Formulary management